drugset / Trial / NCT00172380
Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III
NaSingle-groupOpen-labelTreatment
Summary
To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.
Timeline
- Start
- 2005-02
- Primary completion
- 2010-01
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 36 mg/m2 | — |